Our study shows that in the presence of SF3B1 and SRSF2 mutations, none of the DNMT3A mutant MDS cases had AML transformation, suggesting these mutations are disease and phenotype-defining in the context of DNMT3A R882 mutations. This evidence concerns the gene DNMT3A and acute myeloid leukemia.